Lestaurtinib, a tyrosine kinase inhibitor of FLT3 for treating AML [80,81], could potentially be repositioned for treating NSCLC based on its ability to potently kill and inhibit NSCLC cells and its high relevance in reversing EMT, enhancing drug response, inhibiting proliferation in NSCLC cells, and downregulating survival hazard genes in NSCLC patients. The gene discussed is FLT3; the disease is non-small cell lung carcinoma.